E
Eduardo Collantes-Estevez
Researcher at University of Córdoba (Spain)
Publications - 172
Citations - 9091
Eduardo Collantes-Estevez is an academic researcher from University of Córdoba (Spain). The author has contributed to research in topics: BASDAI & Ankylosing spondylitis. The author has an hindex of 34, co-authored 156 publications receiving 7679 citations. Previous affiliations of Eduardo Collantes-Estevez include Cordoba University & University of Granada.
Papers
More filters
Journal ArticleDOI
Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis
Nuria Barbarroja,Carlos Perez-Sanchez,Patricia Ruiz-Limon,Carmen Castro-Villegas,Maria Angeles Aguirre,Rosario Maria Carretero,P. Segui,Yolanda Jimenez-Gomez,Manuela Sanna,Antonio Rodríguez-Ariza,Eduardo Collantes-Estevez,Alejandro Escudero,Chary López-Pedrera +12 more
TL;DR: Gen expression analysis showed that lymphocytes were major players in altered inflammatory profile, monocytes were responsible for the protrombotic and atherogenic status, and neutrophils mainly displayed a pro-oxidative feature.
Journal ArticleDOI
The burden of ankylosing spondylitis in Spain.
Gisela Kobelt,Patrik Sobocki,Juan Mulero,Jordi Gratacós,Ana Pocovi,Eduardo Collantes-Estevez +5 more
TL;DR: As in studies in other countries, all types of costs accelerate steeply with worsening disease while utility decreases significantly, indicating the need to prevent disease progression.
Journal ArticleDOI
Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment
Patricia Ruiz-Limon,Nuria Barbarroja,Carlos Perez-Sanchez,Maria Angeles Aguirre,Maria Laura Bertolaccini,Munther A. Khamashta,Antonio Rodríguez-Ariza,Yolanda Almaden,P. Segui,Husam Khraiwesh,José A. González-Reyes,José M. Villalba,Eduardo Collantes-Estevez,Maria Jose Cuadrado,Chary López-Pedrera +14 more
TL;DR: The overall data suggest that fluvastatin improves the impairment of a redox-sensitive pathway involved in processes that collectively orchestrate the pathophysiology of atherothrombosis in SLE.
Journal ArticleDOI
Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients.
Carlos Perez-Sanchez,Pilar Font-Ugalde,Patricia Ruiz-Limon,Chary López-Pedrera,M.C. Castro-Villegas,Maria del Carmen Abalos-Aguilera,Nuria Barbarroja,Iván Arias de la Rosa,María Dolores López-Montilla,Alejandro Escudero-Contreras,Clementina López-Medina,Eduardo Collantes-Estevez,Yolanda Jimenez-Gomez +12 more
TL;DR: A six-plasma microRNA signature that could be attractive candidates as non-invasive biomarkers for the AS diagnosis, and may help to elucidate the disease pathogenesis is identified.
Journal ArticleDOI
Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
TL;DR: It is indicated that rofecoxib 25 mg/day is likely to be more effective in patients with OA who do not respond well to celecoxib 200 mg/day and satisfies a large proportion of both patients and physicians.